Table 4 Predictors of favorable outcomes (deaths, LTFU, Rx failure, and NE) between decentralized vs centralized sites in 2016 and 2017

Treatment cohort

 2016

1

1

1

1

 2017

1.4

0.32

1.81

0.14

0.91

0.88

0.78

0.74

0.77

0.078

1.6

0.2

(0.7–2.7)

(0.8–3.9)

(0.22–3.1)

(0.18–3.3)

0.58–1.02

0.75–3.4

Sex

 Female

1

1

1

1

 Male

2.1

0.057

2.14

0.073

0.94

0.91

0.79

0.73

1.3

0.28

1.2

0.38

(0.9–4.9)

(0.92 -5)

(0.3–2.9)

(0.2–3.1)

0.79–2.2

0.7–2.3

HIV

 Positive

1.2

0.52

1.07

0.87

4.7

0.007

4.2

0.02

1.6

0.03

1.5

0.12

(0.6–2.5)

(0.48–2.3)

(1.5–14.7)

(1.2–15)

1.04–2.6

0.8–2.6

 Negative

1

1

1

1

BMI

 ≥ 18.5

1

1

1

1

 < 18.5

3.2

0.002

3.1

0.005

0.99

0.988

0.97

0.97

2.3

0.002

2.2

0.004

(1.6–6.8)

(1.3- 7)

(0.3–2.89)

(0.28- 3.3)

1.3–4

1.3–3.8

Residence

 Urban

1.2

0.47

1.63

0.23

1.5

0.54

2.1

0.175

0.99

0.98

1.3

0.3

(0.6–2.4)

(0.6–4.)

(0.4–5.6)

(0.39–11)

0.6–1.5

0.7–2.6

 Rural

1

1

1

1

Patient group

 New

1

1

1

1

 Retreatment (FLD)

1.14

0.74

0.98

0.99

0.61

0.39

0.48

0.23

1.05

0.85

0.8

0.5

(0.5–2.1)

(0.4–2.43)

(0.2–1.8)

(0.14–1.6)

0.6–1.7

0.4–1.4

Staff training

 Yes

N/A

1

 No

1.25

0.78

1.29

0.79

0.5

0.42

1.01

0.9

(0.25–6.1)

(0.19–8.4)

0.12–2.4

0.19–5.8

Age categories

 < 30 years

1

1

1

1

 31–50 years

3.09

0.02

3.05

0.03

4

0.08

3

0.2

1.9

0.02

2.2

0.02

(1.2–8)

(1.1–8.4)

(0.8–19)

(0.55–16)

1.1–3.5

1.1–4.1

 > 50 years

2.3

0.145

3.1

0.08

3.6

0.178

4

0.18

2.3

0.016

2.6

0.02

(0.7–7.7)

(0.88–8.4)

(0.55–23)

(0.5–33)

1.1–4.7

1.1–5.9

Treatment delivery

 Centralized

N/A

N/A

2.8

0.001

2.9

0.006

 Decentralized

1

1.5–5.1

1.3–6.2